<DOC>
	<DOC>NCT00268216</DOC>
	<brief_summary>The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.</brief_summary>
	<brief_title>Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description>A multicenter, randomized, double-blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criteria: Patients with COPD and FEV1 &lt;60% of predicted normal and baseline (prebronchodilator) FEV1/FVC ratio &lt;70%. Current or exsmokers with a smoking history of at least 10 packyears. Exclusion criteria: Diagnosis of other respiratory disorders (including asthma). Requirement for long term oxygen therapy.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>mortality</keyword>
	<keyword>TORCH</keyword>
	<keyword>SERETIDE</keyword>
	<keyword>ADVAIR</keyword>
	<keyword>COPD</keyword>
</DOC>